Desmopressin is an Effective Treatment for Mixed Nocturia with Nocturnal Polyuria and Decreased Nocturnal Bladder Capacity

Hye Won Lee1, Myung-Soo Choo2, Jeong Gu Lee3, Choal Hee Park4, Jae-Seung Paick5, Jeong Zoo Lee6, Deok Hyun Han7, Won Hee Park8, and Kyu-Sung Lee9

Department of Integrative Bioscience and Biotechnology1, Pohang University of Science and Technology, Pohang; Department of Urology2, Asan Medical Center, University of Ulsan College of Medicine, Seoul; Department of Urology3, Korea University Anam Hospital, Korea University School of Medicine, Seoul; Department of Urology4, Keimyung University School of Medicine, Daegu; Department of Urology5, Seoul National University College of Medicine, Seoul; Department of Urology6, Pusan National University Hospital, Busan; Department of Urology7, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of Urology8, College of Medicine Inha University, Incheon, Korea

To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index [NPI] >33% and a nocturnal bladder capacity index [NBCI] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPI, and NBCI decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia.

Key Words: Urinary Bladder; Deamino Arginine Vasopressin; Hyponatremia; Nocturia; Nocturnal Polyuria

INTRODUCTION

Nocturia is defined as waking one or more times to void during the period between going to bed with the intention of sleeping and waking with the intention of arising (1, 2). Recent multinational population-based, cross-sectional survey (EPIC) of adults aged ≥18 yr using 2002 International Continence Society (ICS) definitions showed overall prevalence of any lower urinary tract symptoms (LUTS) was 62.5% in men and 66.6% in women and nocturia (≥2 times/night) was the most commonly reported symptom (2). Similarly, the epidemiological data in adult Korean aged 40-89 yr national community showed that of 2005 subjects interviewed, 33.5% reported voiding once per night and 48.2% twice or more per night and in addition, the impact of nocturia on daily life was reported by 14.6% of subjects (4). Nocturia is associated with sleep disruption and consequently impairs the quality of life (QOL) and potentially increases mortality (5, 6).

Although this condition should be evaluated and treated, it has only recently been recognized as a clinical entity in its own right, rather than just one of the features of LUTS. Relatively few patients with nocturia seek medical care because of a lack of awareness or misconceptions about nocturia. Furthermore, there is a general lack of knowledge about treatment options for nocturia (4, 7, 8). Because the pathophysiology of nocturia is multifactorial and complex, it is important to adopt a systematic approach to identify the possible causal factors of nocturia and to treat them accordingly. Patients with nocturia can be categorized as having one of the following three disorders: (1) nocturnal polyuria (NP) in which the voided urine volume during the hours of sleep exceeds 33% of the 24-hr output (2), decreased nocturnal bladder capacity (NBC), which results in a nocturnal urinary volume greater than the maximum voided volume (MVV), (3) or mixed nocturia, a combination of the pre-
Desmopressin is a synthetic analogue of arginine vasopressin (AVP), but desmopressin has a more potent antidiuretic effect than AVP. Desmopressin has been shown to be an effective treatment for nocturia with NP by decreasing night-time urine production (12-16). However, a patient with a significantly decreased nocturnal bladder capacity index (NBCi) ≥2 may have bladder outlet obstruction, detrusor overactivity (DO), sensory urgency, and/or primary bladder disorders such as infection, or malignancy (16). Specific treatment of the underlying urological condition would therefore be expected to have a mitigating effect on decreased NBC as a component of nocturia. Although clinicians usually treat nocturia patients with decreased NBC based on their personal experience and use anticholinergic and hypnotic agents as well as desmopressin, these treatments have not been studied extensively clinically. In the present study, we investigated the safety and efficacy of oral desmopressin for the treatment of mixed nocturia in patients with both NP and a decreased NBC.

MATERIALS AND METHODS

Patients aged ≥18 yr with mixed nocturia (≥2 voids/night, nocturnal polyuria index [NPI] >33% and NBCi >1) were enrolled in this open label, prospective, seven-center study. The formula for calculating NPI is simply nocturnal urine volume (NUV) divided by 24-hr urine volume, and NBCi, more complicated formula that addresses voids at night in patients with decreased NBC, is defined as the difference between the predicted number of nightly voids (PNV) and the actual number of nightly voids (ANV). PNV is derived by calculating (NUV/MVV) and subtracting 1 (17). The following exclusion criteria were used: nocturia due to other defined causes of increased urinary frequency, primary polydipsia (>40 mL/kg/24 h), neurogenic bladder dysfunction, urge incontinence, continued post-voiding residual urine >150 mL, serum sodium levels <135 mM/L, uncontrolled hypertension, congestive heart failure, use of diuretics, and actual or planned pregnancy. The study was performed in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, and the principles of the Declaration of Helsinki. The study protocol received ethical committee approval at each study site and written informed consent was obtained from all patients before recruitment into the study.

The study included the following periods: screening (1-week), dose titration (1-3 weeks), and treatment (4 weeks) (Fig. 1). The patients that fulfilled the primary inclusion criteria entered the dose titration phase. During an open-label dose-titration period of up to 3 weeks, the patients’ optimum oral desmopressin dose (0.1, 0.2, or 0.4 mg) was determined as the dose that decreased the number of nocturnal voids by ≥50% or decreased NUV by ≥20% without hyponatremia. If the patients did not meet the above criteria during the dose titration period, they received the maximum tolerable dose instead of the optimum dose. In addition, if the patients complained the adverse effects in spite of good responses to desmopressin during the dose titration period, they received the just lower dose instead of the optimum dose. Then, eligible patients were treated with the determined optimum desmopressin dose for 4 weeks. All patients kept 3-day frequency-volume charts (FVC), recorded bedtime and sleep disruption, and answered a sleep questionnaire at baseline and after treatment. The sleep questionnaire included items about the duration of sleep until the first nocturnal void, the frequency of >5 hr of undisturbed sleep, and the patient’s overall impression about his/her quality of sleep expressed as feeling fresh in the morning or feeling tired in the morning. Clinical and laboratory assessments including body weight, blood and urine analysis, serum sodium monitoring, and adverse event reports were recorded at baseline and after 4 weeks of treatment. The patients with serum sodium levels <125 mM/L, symptomatic hyponatremia, or intolerable adverse effects were withdrawn from the study.

The efficacy assessments were based on data from the patients’ FVC and answers to the sleep questionnaire after the 4-week treatment period. The primary efficacy endpoint was the proportion of patients with a 50% or greater reduction in the mean number of nocturnal voids compared with baseline levels after the 4-week treatment phase. Secondary endpoints included changes in the mean number of nocturnal voids, changes in the mean duration of the period from bedtime to the first nocturnal void (first sleep interval), and the proportion of patients that felt they

Fig. 1. The study design and treatment schedule. NBCi, nocturnal bladder capacity index; NPI, nocturnal polyuria index; NUV, nocturnal urine volume.
had a good sleep experience. The safety of oral desmopressin was evaluated based on the collected adverse events, body weight gain, and laboratory data with an emphasis on serum sodium levels. The significance of the results obtained was tested with a paired t-test or Wilcoxon’s Signed Rank test according to the normality of the data. Binary variables such as the quality of sleep were analyzed using Generalized Estimating Equations (GEE) ($P$ value <.001). A $P$ value of <.05 was considered statistically significant and the statistical software package SPSS version 17.0 was used for data management and analysis.

**Ethnics statement**
The study was performed in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, and the principles of the Declaration of Helsinki. The study protocol, patient information and informed consent forms were reviewed and approved by independent review board at each study and all patients were informed of the nature and purpose of the study (IRB No. 2004-04-05 at Samsung Medical Center). Desmopressin was supplied by Ferring Korea Inc. in 2005. This study was registered as a clinical trial: ClinicalTrials.gov ID: NCT00902655.

**RESULTS**
Among 103 patients enrolled in the dose-titration phase, 9 (8.7%) withdrew due to informed consent withdrawal (n=3) and protocol violation (n=6) during the dose-titration period (Fig. 2). A total of 94 patients received the optimal desmopressin dose, and 90 (95.7%) patients completed the study. Four patients withdrew due to neck stiffness (n=1) or loss to follow-up (n=3). The study population included 79 men (84%) and 15 women (16%) with a median age of 64.2 yr (39–86 yr); their baseline characteristics are summarized in Table 1.

The efficacy analysis included 94 patients that received at least one dose of the study drug during the dose-titration period, had baseline data before the study, and at least one post-baseline efficacy measurement. During the 4 weeks of active treatment, 44% (n=41) of patients received 0.1 mg oral desmopressin, 33% (n=31) received 0.2 mg of desmopressin, and 23% (n=22) received 0.4 mg of desmopressin. Overall patient compliance was high; 84 (89.7%) patients took ≥80% of the prescribed medication during the treatment period.

The mean number of nocturnal voids/night was reduced in at least 50% compared with baseline levels. In 72% of the patients (n=68) (95% CI, 0.63-0.81) ($P<0.001$), the mean number of nocturnal voids decreased significantly from 3.20 to 1.34 after the 4-week treatment with oral desmopressin (Table 1). Furthermore, the total number of voids/24 hr decreased significantly after treatment (11.18 vs 9.15, $P<0.001$); however, the number of mean daytime voids before and after treatment was not significantly different (7.97 vs 7.82, $P=0.38$). Moreover, the factors associated with nocturnal urine production including the mean NUV, NPi, and nocturnal diuresis all decreased significantly after desmopressin treatment. Oral desmopressin treatment was also associated with improved nocturnal bladder capacity as evidenced by decreases in both the nocturia index (Ni) and NBCi (both $P<0.001$).

**Table 1.** The baseline characteristics and comparison of secondary endpoints after 4-week desmopressin treatment (n=94)

| Variable (Mean±SD) | Baseline | Treatment | % change | $P$ value |
|-------------------|----------|-----------|----------|-----------|
| No. of nocturia    | 3.20±1.01| 1.34±0.76 | -57.9    | <0.001    |
| No. of daytime frequency | 7.97±2.52 | 7.82±2.47 | -0.04    | 0.38      |
| No. of 24-hr frequency | 11.18±2.83 | 9.15±2.72 | -17      | <0.001    |
| Nocturnal urine volume (mL) | 725.2±256.1 | 409.2±199.2 | -41.7    | <0.001    |
| Nocturnal diuresis (mL/min) | 1.57±0.53 | 0.92±0.43 | -39.9    | <0.001    |
| Nocturnal polyuria index | 43.49±9.0 | 29.55±9.8 | -31.3    | <0.001    |
| Nocturnal index     | 2.57±0.60 | 1.57±0.58 | -38.9    | <0.001    |
| Nocturnal Bladder Capacity index | 1.62±0.72 | 0.73±0.48 | -54.9    | <0.001    |

The mean duration of sleep until the first nocturnal void increased from 118.4±44.1 to 220.3±90.7 min ($P<0.001$) (Fig. 3A), and 17 (18%) patients had more than 5 hr of undisturbed initial sleep per night after treatment compared to none at baseline (Fig. 3B). The overall impression of patients about their quality of sleep was improved quality; the number of patients who reported a good night of sleep increased significantly from 19.8% to 78.7% after desmopressin treatment for 4 weeks ($P<0.001$) (Fig. 3C).
No significant serum sodium changes (141.8 to 141.5 mM/L, \( P=0.41 \)) or changes in serum creatine (\( P=0.85 \)), potassium (\( P=0.68 \)), or body weight (\( P=0.43 \)) were observed in the safety analysis compared with baseline. One 74-yr-old man treated with 0.1 mg desmopressin for 4 weeks showed significant hyponatremia (132.4 mM/L), but was asymptomatic. Although adverse events occurred in a total of 6 (6.4%) patients treated with a desmopressin dose of 0.2 mg, the symptoms were generally mild (headache [3], facial edema [1], anorexia [1]). One patient withdrew from the study because of neck stiffness.

**DISCUSSION**

Nocturia can be a symptom of several medical disorders other than lower urinary tract abnormalities, and is also a condition in its own right. Therefore, it is important that urologists identify the precise type and causes of nocturia to treat it effectively. For example, in one study, the type of nocturia was classified into three groups based on the voiding diaries and the results of urodynamic study (UDS): Pure NP in which the voided urine volume during the hours of sleep is more than 35% of the 24-hr urine volume, DO defined as existing uninhibited contraction on filling cystometrogram, and mixed (NP with DO). They reported that the proportion of NP, DO and mixed type were 50.0%, 7.9%, and 17.1% respectively (18). In general, nocturia can be categorized into three types: NP, decreased NBC, mixed nocturia with a combination of NP and decreased NBC, or global polyuria which refers to urine overproduction over a 24-hr period (19). Pharmacological options that could be considered include the cautious use of loop diuretics in the afternoon, anti-muscarinics for decreased NBC, and desmopressin for nocturia caused by NP. Because the number of patients with mixed nocturia has been underestimated and few results about the effect of desmopressin on mixed nocturia have been reported, we analyzed the clinical effects of oral desmopressin on patients with mixed nocturia by evaluating the improvements in both NP and NBC.

The results of our study showed that treatment with desmopressin for 4 weeks resulted in a significant improvement in the parameters associated with NP including NUV (41.7% reduction), NPi (31.3% reduction), and nocturnal diuresis (39.9% reduction). NP is believed to be responsible for at least 50–65% of nocturia cases (9, 20). The hormone AVP is normally released into the circulation following the diurnal pattern linked to the wake-sleep cycle, and decreases urine production by promoting osmotic re-absorption of solute-free water in the collecting tubules (21). Oral desmopressin, is effective against NP because it compensates for loss of circadian rhythm-related ADH secretion and furthermore, it causes slight changes in drinking habits. In one randomized, double-blind, placebo-controlled study for men ≥18 yr with verified nocturia and Ni >1, the decrease in the mean number of nocturnal voids (from 3.0 to 1.7), mean nocturnal diuresis (from 1.5 to 0.9 mL/min), and mean ratio of night/24-hr urine volume (23%) were significantly different between the desmopressin and placebo groups (all \( P<0.001 \)) (15).

Rembratt et al. (22) also found in a short-term study that desmopressin treatment reduced the mean number of nocturnal voids and there was a reduction of ≥20% in nocturnal diuresis in 58 patients (82%) and of ≥50% in 31 (44%). The effects of desmopressin on the NP component of nocturia in patients with mixed nocturia in the present study are similar to those reported in previous studies which inclusion criteria were not limited to mixed nocturia.

However, the use of desmopressin for the treatment of nocturia with decreased NBC has not been thoroughly evaluated, and a standard treatment protocol aimed at improving the decrease in NBC has not been developed to date. Our results suggest that oral desmopressin improves nocturia by increasing NBC as well as decreasing NUV, which is reflected by improved Ni (38.9% reduction) and NBCi (54.9% reduction). Desmopressin most likely improves NBC as follows. Type E2 neurons in and around the micturition center directly regulate the activity of the bladder, and type E1 and type I neurons modulate the activity of type E2 neurons by excitatory and inhibitory effects (23). Desmopressin suppresses bladder activity by inhibiting type E1 neu-
rons or activating type I neurons. Moreover, ureterovesical flow has been demonstrated to trigger local and general detrusor activity in an unstable bladder by distension of detrusor muscle bundles around the ureteric hiatus detrusor activity in a pig model (24). Based on these findings, desmopressin treatment would improve the decreased NBC seen in mixed nocturia patients by suppressing detrusor activity and inhibiting neuron-associated bladder contraction and the ureterovesical flow rate during sleep.

The mean duration of the time until the first nocturnal void in patients with mixed nocturia was prolonged by desmopressin and the patients’ overall impression about their quality of sleep improved due to a decrease in the frequency of nocturnal voids in the present study. Similarly, Van Kerrebroeck et al. showed that the duration of the first sleep period was prolonged by 108 min (placebo group: 41 min, \( P<0.001 \)) and an average of >5 hr of unbroken first sleep period per night was experienced by 27% of desmopressin-treated patients (placebo group: 9%), resulting in a highly significant between-group difference (25). These authors reported that two questions concerning the quality of deep stages of sleep with a decreased nocturnal voiding frequency may therefore be sufficient to maintain water and electrolyte balance (29, 30). In addition, at least a 10-fold higher-than-recommended dose did not cause changes in the serum sodium concentration.

In conclusion, oral desmopressin treatment results in a significant improvement in the number of mixed nocturia episodes by reducing NUV and increasing NBC. This drug improves the quality of sleep by prolonging the period of sleep until the first void, and is shown to have an acceptable safety profile.

ACKNOWLEDGMENT

Desmopressin was supplied by Ferring Korea Inc. in 2005.

REFERENCES

1. Van Kerrebroeck PE. Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents. BJU Int 2002; 89: 420-3.
2. Malmsten UG, Milsom I, Molander U, Norlén LJ. Urinary incontinence and lower urinary tract symptoms: an epidemiological study of men aged 45 to 99 years. J Urol 1997; 158: 1733-7.
3. Irvin DE, Milsom I, Hanskaa S, Reily K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14.
4. Choo MS, Ku JH, Park CH, Lee YS, Lee KS, Lee JG, Park WH. Prevalence of nocturia in a Korean population aged 40 to 89 years. Neurourol Urodyn 2008; 27: 60-4.
5. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992; 10: 98-104.
6. Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int 1999; 83: 591-5.
7. Bing MH, Moller LA, Jennum P, Mortensen S, Skovgaard LT, Lose G. Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years. BJU Int 2006; 98: 599-604.
8. Chen FY, Dai YT, Liu CK, Yu HJ, Liu CY, Chen TH. Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 431-6.
9. Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: etiology and classification. Neurourol Urodyn 1998; 17: 467-72.
10. Marinkovic SP, Gillen LM, Stanton SL. Managing nocturia. BJM 2004; 328: 1063-6.
11. Van Kerrebroeck P, Abrams P, Chaiakin D, Donovan J, Fonda D, Jackson S, Jennum P, Johnson T, Lose G, Matsuasson A, Robertson G, Weiss J. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 179-83.
12. Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study. Br J Urol 1998; 82: 642-6.
13. Belmaker RH, Bleich A. The use of desmopressin in adult enuresis. Mil...
14. Vilhardt H. Basic pharmacology of desmopressin. A review. Drug Invest 1996; 2 (Suppl 5): 2-8.
15. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89: 855-62.
16. Nam SG, Moon DG, Kim JJ. Efficacy of desmopressin in treatment of adult nocturia. Korean J Urol 2004; 45: 49-55.
17. Weiss JP, Blaivas JG. Nocturia. Curr Urol Rep 2003; 4: 362-6.
18. Kim ET, Lee SI, Lee KS. The etiology and classification of nocturia in adults. Korean J Urol 2001; 42: 1075-9.
19. Weiss JP. Nocturia: “do the math.” J Urol 2006; 175: S16-8.
20. Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J (Clin Res Ed) 1983; 287: 1665-7.
21. Nadal M. Secretory rhythm of vasopressin in healthy subjects with inverted sleepwake cycle: evidence for the existence of an intrinsic regulation. Eur J Endocrinol 1996; 134: 174-6.
22. Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003; 91: 642-6.
23. Iwasaki H, Koyama Y, Tanaka Y, Kawauchi A, Jodo E, Kayama Y, Miki T. Modulation by desmopressin of neuronal activity in brainstem micturition center. Urology 2004; 63: 994-8.
24. Blok C, Coolsaet BL, Mansour M, Razzouk A. Dynamics of the ureterovesical junction: interaction between diuresis and detrusor instability at the ureterovesical junction in pigs. J Urol 1986; 136: 1123-6.
25. Van Kerrebroeck P, Rezapour M, Cortesse A, Thürloff J, Riis A, Nørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol 2007; 52: 221-9.
26. Thomas S. Some effects of changes of posture on water and electrolyte excretion by the human kidney. J Physiol 1957; 139: 337-52.
27. Bae JH, Oh MM, Shim KS, Cheon J, Lee JG, Kim JJ, Moon DG. The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study. J Urol 2007; 178: 200-3.
28. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurol Urodyn 2004; 23: 302-5.
29. Rittig S, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998; 48: 235-41.
30. Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol 1998; 57: 153-9.